Waters (NYSE:WAT) Price Target Raised to $360.00

Waters (NYSE:WAT) had its target price upped by Sanford C. Bernstein from $345.00 to $360.00 in a research note published on Monday morning,Benzinga reports. The firm currently has a market perform rating on the medical instruments supplier’s stock.

Other analysts also recently issued reports about the stock. JPMorgan Chase & Co. boosted their target price on shares of Waters from $340.00 to $380.00 and gave the stock a “neutral” rating in a research report on Monday. The Goldman Sachs Group raised shares of Waters to a “hold” rating in a research report on Wednesday, July 31st. Leerink Partnrs raised shares of Waters from a “hold” rating to a “strong-buy” rating in a report on Thursday, August 1st. Deutsche Bank Aktiengesellschaft decreased their price objective on shares of Waters from $330.00 to $310.00 and set a “hold” rating for the company in a report on Thursday, August 1st. Finally, Stifel Nicolaus upped their price objective on shares of Waters from $332.00 to $360.00 and gave the stock a “hold” rating in a report on Monday. One equities research analyst has rated the stock with a sell rating, ten have assigned a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $365.85.

Waters Stock Down 0.1 %

Waters stock opened at $386.17 on Monday. The firm has a market cap of $22.93 billion, a PE ratio of 36.85, a P/E/G ratio of 7.07 and a beta of 0.97. The company has a debt-to-equity ratio of 1.14, a quick ratio of 0.55 and a current ratio of 2.02. The firm’s 50 day moving average price is $345.80 and its two-hundred day moving average price is $327.56. Waters has a twelve month low of $246.35 and a twelve month high of $393.38.

Waters (NYSE:WAT) last released its quarterly earnings data on Friday, November 1st. The medical instruments supplier reported $2.93 earnings per share for the quarter, beating the consensus estimate of $2.68 by $0.25. The firm had revenue of $740.30 million for the quarter, compared to analyst estimates of $712.99 million. Waters had a net margin of 21.43% and a return on equity of 49.93%. The company’s revenue for the quarter was up 4.0% compared to the same quarter last year. During the same quarter in the prior year, the business earned $2.84 EPS. On average, research analysts predict that Waters will post 11.79 EPS for the current fiscal year.

Hedge Funds Weigh In On Waters

Hedge funds have recently made changes to their positions in the business. Kennebec Savings Bank acquired a new position in shares of Waters in the 3rd quarter valued at $33,000. Ashton Thomas Securities LLC acquired a new position in shares of Waters in the 3rd quarter valued at $35,000. Itau Unibanco Holding S.A. acquired a new position in shares of Waters in the 2nd quarter valued at $33,000. Blue Trust Inc. raised its stake in shares of Waters by 190.2% in the 2nd quarter. Blue Trust Inc. now owns 119 shares of the medical instruments supplier’s stock valued at $35,000 after buying an additional 78 shares in the last quarter. Finally, TFC Financial Management Inc. increased its position in shares of Waters by 19,900.0% during the 2nd quarter. TFC Financial Management Inc. now owns 200 shares of the medical instruments supplier’s stock worth $58,000 after purchasing an additional 199 shares in the last quarter. Institutional investors and hedge funds own 94.01% of the company’s stock.

About Waters

Waters Corporation provides analytical workflow solutions in Asia, the Americas, and Europe. It operates through two segments: Waters and TA. The company designs, manufactures, sells, and services high and ultra-performance liquid chromatography, as well as mass spectrometry (MS) technology systems and support products, including chromatography columns, other consumable products, and post-warranty service plans.